Luseogliflozin CAS:898537-18-3

Luseogliflozin is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2)inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus(T2DM).Our products are only suitable for scientific research experiments, not for clinical experiments and human body.

msds----Luseogliflozin